Scholarlink

Introduction <p>Treat-to-target strategies for rheumatoid arthritis (RA) aim for remission or low disease activity (LDA) and improve long-term outcomes. The objective of this analysis is to report early achievement of remission or LDA at 3&#xa0;months (M) in a real-world RA population and explore the long-term (2&#xa0;years) outcomes of achieving early remission/LDA.</p> Methods <p>RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with RA. Patients initiated treatment with baricitinib (cohort A) or any biologic (b) disease-modifying anti-rheumatic drug (DMARD) or any other targeted synthetic (ts) (cohort B) for the first time. This analysis covers data from a European subpopulation of RA-BE-REAL. Effectiveness data at 3&#xa0;months (early remission), and 24&#xa0;months were presented descriptively. Logistic regression was used to determine associations between baseline characteristics and achievement of remission/LDA at 3&#xa0;months and also associations between early remission/LDA and subsequent achievement of long-term remission/LDA at 24&#xa0;months.</p> Results <p>At 3&#xa0;months, high proportions of patients in both cohorts (cohort A: 59.4%, cohort B: 49.3%) reached remission or LDA. Patients achieving early remission or LDA had greater improvement in short- and long-term pain, functioning (HAQ-DI), and quality of life (EQ-5D-5L) than those who did not. Logistic regression found that previous experience with ≥ 2 previous b/tsDMARDs, higher Clinical Disease Activity Index (CDAI) scores, and lower EQ-5D-5L scores at baseline were negative predictors for the achievement of early remission or LDA. Furthermore, achievement of remission or LDA at 3&#xa0;months was associated with remission or LDA at 24&#xa0;months.</p> Conclusions <p>In a routine clinical practice population, achieving early remission/LDA was associated with maintained remission/LDA at 2&#xa0;years as well as long-term improvement in pain, physical function, and quality of life in both cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月23日

查看全文
  • Rieke Alten,
  • Andrew Östör,
  • Christopher J. Edwards,
  • Josef S. Smolen,
  • Ewa Haladyj,
  • Khai Jing Ng,
  • Samuel Ogwu,
  • Yuko Kaneko

摘要

Introduction

Treat-to-target strategies for rheumatoid arthritis (RA) aim for remission or low disease activity (LDA) and improve long-term outcomes. The objective of this analysis is to report early achievement of remission or LDA at 3 months (M) in a real-world RA population and explore the long-term (2 years) outcomes of achieving early remission/LDA.

Methods

RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with RA. Patients initiated treatment with baricitinib (cohort A) or any biologic (b) disease-modifying anti-rheumatic drug (DMARD) or any other targeted synthetic (ts) (cohort B) for the first time. This analysis covers data from a European subpopulation of RA-BE-REAL. Effectiveness data at 3 months (early remission), and 24 months were presented descriptively. Logistic regression was used to determine associations between baseline characteristics and achievement of remission/LDA at 3 months and also associations between early remission/LDA and subsequent achievement of long-term remission/LDA at 24 months.

Results

At 3 months, high proportions of patients in both cohorts (cohort A: 59.4%, cohort B: 49.3%) reached remission or LDA. Patients achieving early remission or LDA had greater improvement in short- and long-term pain, functioning (HAQ-DI), and quality of life (EQ-5D-5L) than those who did not. Logistic regression found that previous experience with ≥ 2 previous b/tsDMARDs, higher Clinical Disease Activity Index (CDAI) scores, and lower EQ-5D-5L scores at baseline were negative predictors for the achievement of early remission or LDA. Furthermore, achievement of remission or LDA at 3 months was associated with remission or LDA at 24 months.

Conclusions

In a routine clinical practice population, achieving early remission/LDA was associated with maintained remission/LDA at 2 years as well as long-term improvement in pain, physical function, and quality of life in both cohorts.